Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide, Ibrutinib, and Rituximab in Relapsed/Refractory CLL and SLL
NCT02160015Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2014
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenalidomide and ibrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by National Cancer Institute. Primary endpoint: Recommended Phase II Dose up to 28 days. Started May 2014; status: active, not recruiting.
02
Drugs
lenalidomideibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02160015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02160015.